Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study

PURPOSE: The vascular disrupting agent fosbretabulin tromethamine selectively targets pre-existing tumor vasculature, which causes vascular shutdown and leads to cancer cell death and necrosis. Antiangiogenesis agents such as bevacizumab, a humanized antivascular endothelial growth factor monoclonal...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Clin Oncol
Main Authors: Monk, Bradley J., Sill, Michael W., Walker, Joan L., Darus, Christopher J., Sutton, Gregory, Tewari, Krishnansu S., Martin, Lainie P., Schilder, Jeanne M., Coleman, Robert L., Balkissoon, Jai, Aghajanian, Carol
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2016
Teme:
ORIGINAL REPORTS
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4962710/
https://ncbi.nlm.nih.gov/pubmed/27217446
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.65.8153
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki